Business News • PR NewsWire • Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH

Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH

Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH

OSLO, Dec. 3, 2018 /PRNewswire/ -- Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin's lymphoma (iNHL) Highly active in follicular lymphoma (FL) patients with ≥2 prior therapies (n=37) (ORR 70% CR 32%), and...

View More : https://www.prnewswire.com:443/news-releases/nordic-nanovector-single-administration-betalutin-r-is-effective-and-well-t...

Releted News by prnewswire

AEM Unveils CONEXPO Connect Powered by Balluun, a B2B Marketplace for the Global Construction Industry

SAFR, Advanced Facial Recognition Technology from RealNetworks, Enters the China Market Through Homtar Corporation

Disposable Gloves Market Worth $14.93 Billion By 2025 | CAGR 7.8%: Grand View Research, Inc.

Third Point Offshore Investors Ltd - Corporate Update and Share Buyback Programme